Dedicated catheters for hepatic arterial infusion chemotherapy were removed from the market. The purpose of this study was to assess the results of a novel approach to overcome the shortage of dedicated catheters for hepatic arterial infusion chemotherapy in the treatment of colorectal cancer liver metastases. We retrospectively included patients who underwent a percutaneous placement of a hepatic intra-arterial port catheter in a single tertiary center from February 2021 to June 2022. We examined the patient baseline characteristics, technical features of the modified procedures, technical success rates, complications and oncological outcomes. Fourteen patients (median age: 60 years; q1 = 54; q3 = 70; range: 53–81 years) underwent 15 modified procedures. The main modification of our placement technique consisted of the use of an indwelling 5-Fr Vertebral catheter, on the tip of which we created a two-sided additional lateral hole. The catheter was connected to a pediatric port. The primary success rate was 100%, and the secondary success rate was 93.3%. There were two late major complications, graded IIIa according to the Clavien–Dindo classification. The median liver progression free survival was 6.1 months (q1 = 2.5; q3 = 7.2; range: 1.3–11.6). Our experience suggests that the derived utilization of the devices used routinely in interventional radiology provides an effective solution that can compensate for the shortage of dedicated devices.
用于肝动脉灌注化疗的专用导管已退出市场。本研究旨在评估一种新方法在克服结直肠癌肝转移治疗中肝动脉灌注化疗专用导管短缺问题上的应用效果。我们回顾性纳入了2021年2月至2022年6月期间在单一三级医疗中心接受经皮肝动脉输液港导管置入术的患者。分析了患者基线特征、改良术式的技术特点、技术成功率、并发症及肿瘤学结局。14名患者（中位年龄60岁；q1=54；q3=70；范围53-81岁）共接受了15次改良手术。置入技术的主要改良在于使用留置型5-Fr椎动脉导管，在其尖端额外创建双侧侧孔，导管连接儿童用输液港。初次技术成功率为100%，二次成功率为93.3%。根据Clavien-Dindo分级标准，发生2例IIIa级晚期主要并发症。中位肝脏无进展生存期为6.1个月（q1=2.5；q3=7.2；范围1.3-11.6）。我们的经验表明，通过对介入放射学常规器械进行改良应用，可提供有效解决方案以弥补专用器械的短缺。
肿瘤(癌症)患者之家